Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative.
Lee
J H
JH
CKD Research Institute, CKD Pharmaceutical Corporation, Seoul 152-600, Korea.
Lee
J M
JM
Lim
K H
KH
Kim
J K
JK
Ahn
S K
SK
Bang
Y J
YJ
Hong
C I
CI
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000494:pharmacology*; D002166:Camptothecin / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D059004:Topoisomerase I Inhibitors; D014407:Tumor Cells, Cultured / Q000187:drug effects
D000970:Antineoplastic Agents; D059004:Topoisomerase I Inhibitors; C116963:belotecan; D002166:Camptothecin